Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo
about
The dual role of complement in cancer and its implication in anti-tumor therapyMonoclonal antibodies for the treatment of cancerImmunotherapy in human colorectal cancer: Challenges and prospectiveAnalysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models.The role of complement in tumor growthCTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.Cetuximab and biomarkers in non-small-cell lung carcinomaCharacterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2.A monoclonal antibody against KCNK9 K(+) channel extracellular domain inhibits tumour growth and metastasis.Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.CD59 Regulation by SOX2 Is Required for Epithelial Cancer Stem Cells to Evade Complement Surveillance.Combining immunotherapy and targeted therapies in cancer treatment.Complement inhibition in cancer therapy.Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells.Regulation of complement-dependent cytotoxicity by TGF-β-induced epithelial-mesenchymal transition.Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).A simple synthesis of a targeted drug delivery system with enhanced cytotoxicity.Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests.A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer.The efficacy of cetuximab in a tissue-engineered three-dimensional in vitro model of colorectal cancer.Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas.An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations.Complement as a Biological Tool to Control Tumor Growth
P2860
Q26738682-40509A87-86F2-4593-973D-0DEAA39A681BQ27025966-65E836A4-2CB2-44E5-A77C-D3AA3A2BD187Q28068788-2A256271-C53C-4A87-BAE9-2641137FB2EBQ33893381-608BC842-4DBA-4A21-95A6-52F7749B6CA6Q35231345-9E20EB22-591F-48F3-9D14-29D0186B8F2BQ35674757-3351CDA9-9AFB-41AD-8DE6-42712C08D883Q36171281-C6DF48EA-0978-4136-8DED-CF1094A5E322Q36216327-03EB5C6C-A051-4135-90E6-DF0DEFA132F7Q36548721-C6BC2926-7B03-4C2F-A65A-B700A7EAC44AQ36624335-7C311684-C6E8-46EE-AB2A-2ACEBF7BC833Q37583589-422C190A-BDC7-46B7-830C-5DB7CBB57173Q37995939-94C75A66-797A-4A8F-8508-0BEDD501CA0EQ38109340-D7312584-9A4E-4560-9406-AD26B1830AEDQ38214511-C13A7DD2-F937-44DC-A412-D0E86330A93BQ38722574-F29357D0-D924-4608-976B-921518F842BFQ38827226-3E9FB6DF-ECB8-4894-995B-3196922F6C57Q38856280-EC5731F9-6FB2-49F6-AB73-52B9473F0F4BQ39515308-6971333D-1E6A-4B59-A4BB-CA7D5505B59CQ39515675-EBB8D023-BF39-4EA1-B39B-FF6CEA5A5019Q39696362-4A7A7CD0-9645-402D-B4DF-5645515EEC98Q41664652-DE948418-31F0-4619-9811-D260BD1EAFEEQ42044314-01F388EE-79C4-48CB-B4B3-DD31448B5E18Q49672464-8B1E0118-C4D7-4A54-80B9-1143256047C8Q55439903-D687FF16-EB10-40B6-A36A-98B8C1284DDDQ57492005-389E2CB8-3EA3-4653-8870-73B48B9A8BF4
P2860
Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo
description
2010 nî lūn-bûn
@nan
2010 թուականին հրատարակուած գիտական յօդուած
@hyw
2010 թվականին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Complement activation mediates ...... ng cancer tumor growth in vivo
@ast
Complement activation mediates ...... ng cancer tumor growth in vivo
@en
Complement activation mediates ...... ng cancer tumor growth in vivo
@en-gb
Complement activation mediates ...... ng cancer tumor growth in vivo
@nl
type
label
Complement activation mediates ...... ng cancer tumor growth in vivo
@ast
Complement activation mediates ...... ng cancer tumor growth in vivo
@en
Complement activation mediates ...... ng cancer tumor growth in vivo
@en-gb
Complement activation mediates ...... ng cancer tumor growth in vivo
@nl
prefLabel
Complement activation mediates ...... ng cancer tumor growth in vivo
@ast
Complement activation mediates ...... ng cancer tumor growth in vivo
@en
Complement activation mediates ...... ng cancer tumor growth in vivo
@en-gb
Complement activation mediates ...... ng cancer tumor growth in vivo
@nl
P2093
P2860
P3181
P356
P1433
P1476
Complement activation mediates ...... ng cancer tumor growth in vivo
@en
P2093
Alfonso Gurpide
Daniel Ajona
Leticia Corrales
Luis M Montuenga
Yi-Fan Hsu
P2860
P2888
P3181
P356
10.1186/1476-4598-9-139
P407
P577
2010-06-07T00:00:00Z
P5875
P6179
1031107658